{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:01:23Z","timestamp":1790719283192,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jhepr.2024.101116","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:46:12Z","timestamp":1715269572000},"page":"101116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Direct oral anticoagulants in cirrhosis: Rationale and current evidence"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-8498","authenticated-orcid":false,"given":"Cindy","family":"Pereira Portela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas A.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-8268","authenticated-orcid":false,"given":"Maxime G.","family":"Zermatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Moradpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9756-4974","authenticated-orcid":false,"given":"Debora","family":"Bertaggia Calderara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Veuthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-2340","authenticated-orcid":false,"given":"Andrea","family":"De Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-264X","authenticated-orcid":false,"given":"Guido","family":"Stirnimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-9920","authenticated-orcid":false,"given":"Lorenzo","family":"Alberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib1","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/hep.31201","article-title":"Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis","volume":"71","author":"Zermatten","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/j.gastro.2009.08.045","article-title":"An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis","volume":"137","author":"Tripodi","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib3","article-title":"Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis","volume":"2","author":"Zermatten","year":"2020","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis","volume":"117","author":"Ambrosino","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101116_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/hep.20569","article-title":"Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests","volume":"41","author":"Tripodi","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hep.23653","article-title":"Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method","volume":"52","author":"Tripodi","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101116_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.thromres.2014.07.010","article-title":"Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions","volume":"134","author":"Groeneveld","year":"2014","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jgh.13493","article-title":"Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis","volume":"32","author":"Lebreton","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101116_bib9","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/j.1538-7836.2010.03937.x","article-title":"Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy","volume":"8","author":"Gatt","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jhepr.2024.101116_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/856754","article-title":"Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay","volume":"2013","author":"Youngwon","year":"2013","journal-title":"Biomed Res Int"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2024.101116_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ijlh.13856","article-title":"Pathophysiology and management of bleeding and thrombosis in patients with liver disease","volume":"44","author":"van den Boom","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2023.10.008","article-title":"Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis","volume":"22","author":"Zanetto","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1055\/s-0040-1718924","article-title":"Fibrinolysis in patients with liver disease","volume":"47","author":"von Meijenfeldt","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1055\/s-0040-1715102","article-title":"Thrombin generation and cirrhosis: state of the art and perspectives","volume":"46","author":"Lebreton","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jtha.2023.02.002","article-title":"Intraindividual variability over time of thrombin generation in patients with cirrhosis","volume":"21","author":"Sinegre","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101116_bib16","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/jth.14963","article-title":"Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with ST-Genesia","volume":"18","author":"Talon","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-0040-1714205","article-title":"Incidence of bleeding and thrombosis in patients with liver disease","volume":"46","author":"Roberts","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib18","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/hep.32019","article-title":"Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nation-wide cohort study","volume":"74","author":"Jepsen","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3350\/cmh.2016.0110","article-title":"Anticoagulation in cirrhosis: a new paradigm?","volume":"23","author":"Leonardi","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"issue":"8","key":"10.1016\/j.jhepr.2024.101116_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/qjmed\/hcz127","article-title":"Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis","volume":"112","author":"Lapumnuaypol","year":"2019","journal-title":"QJM"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10557-020-07065-y","article-title":"Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review","volume":"35","author":"Huang","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jhepr.2024.101116_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.08.011","article-title":"Direct oral anticoagulants in patients with liver cirrhosis: a systematic review","volume":"170","author":"Hoolwerf","year":"2018","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","volume":"54","author":"Koh","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-021-00482-w","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis","volume":"22","author":"Lee","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jhepr.2024.101116_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8859602","article-title":"Safety and efficacy of anticoagulation in patients with cirrhosis: a meta-analysis","volume":"2021","author":"Chen","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib28","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/hep.29370","article-title":"Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies","volume":"67","author":"Ardevol","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000381305","article-title":"Alcohol abuse and alcoholic liver cirrhosis leading to spontaneous muscle hematoma: an event fraught with danger","volume":"9","author":"Mangla","year":"2015","journal-title":"Case Rep Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101116_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.005","article-title":"Association between liver disease and intracranial hemorrhage","volume":"25","author":"Parikh","year":"2016","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"12","key":"10.1016\/j.jhepr.2024.101116_bib31","first-page":"815","article-title":"Increased risk of subdural hematoma in patients with liver cirrhosis","volume":"110","author":"Lin","year":"2017","journal-title":"QJM"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.27106","article-title":"Long-term risk of venous thromboembolism among patients with gastrointestinal non-neoplastic and neoplastic diseases: a prospective cohort study of 484 211 individuals","volume":"99","author":"Yuan","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib33","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","article-title":"Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors","volume":"75","author":"Turon","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/hematology.2021000283","article-title":"Rebalanced hemostasis in liver disease: a misunderstood coagulopathy","volume":"2021","author":"Roberts","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101116_bib35","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/jth.15364","article-title":"Treatment of bleeding in patients with liver disease","volume":"19","author":"Northup","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.15562","article-title":"Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH","volume":"20","author":"Roberts","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jhep.2021.11.004","article-title":"Haemostatic alterations and management of haemostasis in patients with cirrhosis","volume":"76","author":"Lisman","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib38","first-page":"e21","article-title":"[Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome]","volume":"140","author":"Nguyen-Tat","year":"2015","journal-title":"Dtsch Med Wochenschr"},{"issue":"23","key":"10.1016\/j.jhepr.2024.101116_bib39","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study","volume":"305","author":"Lebrec","year":"1981","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib40","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension","volume":"43","author":"Turco","year":"2023","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib43","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/jth.14011","article-title":"Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis","volume":"16","author":"Sinegre","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101116_bib44","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1365-2036.2010.04454.x","article-title":"The epidemiology and clinical features of portal vein thrombosis: a multicentre study","volume":"32","author":"Rajani","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2024.101116_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.032","article-title":"Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"104","author":"Pan","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100055","article-title":"Fibrin clot properties and thrombus composition in cirrhosis","volume":"7","author":"Driever","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"10.1016\/j.jhepr.2024.101116_bib47","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.dld.2022.06.004","article-title":"ADAMTS-13\/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study","volume":"54","author":"Sacco","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib48","first-page":"557","article-title":"Anticoagulation in patients with atrial fibrillation and liver cirrhosis","volume":"35","author":"Karapedi","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101116_bib49","unstructured":"European Medicines Agency. Eliquis \u00ae\u2014summary of product characteristics [cited 21.08.2023] [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis."},{"key":"10.1016\/j.jhepr.2024.101116_bib50","unstructured":"European Medicines Agency. Lixiana \u00ae\u2014summary of product characteristics [cited 21.08.2023] [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lixiana."},{"key":"10.1016\/j.jhepr.2024.101116_bib51","unstructured":"European Medicines Agency. Xarelto \u00ae\u2014summary of product characteristics [cited 21.08.2023] [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto."},{"key":"10.1016\/j.jhepr.2024.101116_bib52","unstructured":"European Medicines Agency. Pradaxa\u00ae\u2014summary of product characteristics [cited 21.08.2023] [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pradaxa."},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib53","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1053\/j.gastro.2021.08.015","article-title":"AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis","volume":"161","author":"O'Shea","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101116_bib55","doi-asserted-by":"crossref","unstructured":"Puente Sanchez A TF MJ, Ignacio Fortea J, Garcia Pagan JC. GS-003 - rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial. In: Hepatology Jo, editor. European association for the study of liver (EASL) Vienna, Austria2023.","DOI":"10.1016\/S0168-8278(23)00442-7"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2024.101116_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12072-017-9826-x","article-title":"Biology of portal hypertension","volume":"12","author":"McConnell","year":"2018","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib57","doi-asserted-by":"crossref","first-page":"G171","DOI":"10.1152\/ajpgi.00402.2017","article-title":"Role of the blood coagulation cascade in hepatic fibrosis","volume":"315","author":"Pant","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib58","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib59","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib60","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2021.12.038","article-title":"Factor VIII\/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD","volume":"76","author":"Scheiner","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101116_bib61","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2022.03.009","article-title":"Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death","volume":"77","author":"Zanetto","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101116_bib62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","article-title":"Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences","volume":"116","author":"Lisman","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2013.03.027","article-title":"Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats","volume":"59","author":"Lisman","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.jhepr.2024.101116_bib64","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0034-1395160","article-title":"From vitamin K antagonists to liver international normalized ratio: a historical journey and critical perspective","volume":"40","author":"Gatt","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100052","article-title":"Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis","volume":"7","author":"Lisman","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/lt.20906","article-title":"MELD-XI: a rational approach to \"sickest first\" liver transplantation in cirrhotic patients requiring anticoagulant therapy","volume":"13","author":"Heuman","year":"2007","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101116_bib67","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1538-7836.2012.04824.x","article-title":"Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis","volume":"10","author":"Senzolo","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","article-title":"Low-molecular-weight heparin in patients with advanced cirrhosis","volume":"31","author":"Bechmann","year":"2011","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib69","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.12593","article-title":"Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis","volume":"163","author":"Potze","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101116_bib70","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1160\/th15-04-0354","article-title":"Role of exosite binding modulators in the inhibition of Fxa by TFPI","volume":"115","author":"Peraramelli","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1 Suppl","key":"10.1016\/j.jhepr.2024.101116_bib71","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jhepr.2024.101116_bib72","doi-asserted-by":"crossref","first-page":"985","DOI":"10.12688\/f1000research.11174.1","article-title":"Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants","volume":"6","author":"Weitz","year":"2017","journal-title":"F1000Res"},{"issue":"16","key":"10.1016\/j.jhepr.2024.101116_bib73","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197583","article-title":"Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis","volume":"13","author":"Makam","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib76","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"10.1016\/j.jhepr.2024.101116_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhepr.2024.101116_bib79","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2174\/1389200218666170427113504","article-title":"Dabigatran-metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Antonijevic","year":"2017","journal-title":"Curr Drug Metab"},{"issue":"13","key":"10.1016\/j.jhepr.2024.101116_bib80","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.jhepr.2024.101116_bib81","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the\u00a0pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"PI-84","key":"10.1016\/j.jhepr.2024.101116_bib83","first-page":"S34","article-title":"Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment","volume":"85","author":"Frost","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.jhepr.2024.101116_bib84","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jhepr.2024.101116_bib85","unstructured":"Lexicomp\u00ae drug interactions [Internet]. [cited 13.09.2023]. Available from: https:\/\/www.uptodate.com\/drug-interactions\/?source=responsive_home#di-druglist."},{"key":"10.1016\/j.jhepr.2024.101116_bib86","unstructured":"Epocrates web MultiCheck [Internet]. [cited 15.09.2023]. Available from: https:\/\/www.epocrates.com\/online\/interaction-check."},{"key":"10.1016\/j.jhepr.2024.101116_bib87","unstructured":"DDI-predictor [Internet]. [cited 15.09.2023]. Available from: https:\/\/www.ddi-predictor.org\/predictor\/ddi-cirrhosis."},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib88","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1113-0655","article-title":"Does one dose really fit all? On the monitoring of direct oral anticoagulants: a review of the literature","volume":"40","author":"Moner-Banet","year":"2020","journal-title":"Hamostaseologie"},{"issue":"11","key":"10.1016\/j.jhepr.2024.101116_bib89","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/liv.13882","article-title":"In\u00a0vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis","volume":"38","author":"Lisman","year":"2018","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088390","article-title":"Differential in\u00a0vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis","volume":"9","author":"Potze","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib91","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.27350","article-title":"Decreased in\u00a0vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis","volume":"61","author":"Potze","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101116_bib92","unstructured":"US food and drug administration - lixiana [cited 02.04.2024] [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf."},{"issue":"12","key":"10.1016\/j.jhepr.2024.101116_bib93","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"Bathala","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"10.1016\/j.jhepr.2024.101116_bib94","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood.2020005319","article-title":"Anticoagulant activity of edoxaban in patients with cirrhosis","volume":"136","author":"Bos","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib95","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhepr.2024.101116_bib96","unstructured":"US food and drug administration - eliquis [cited 02.04.2024] [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf."},{"key":"10.1016\/j.jhepr.2024.101116_bib97","unstructured":"US food and drug administration - xarelto [cited 02.04.2024] [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022406s015lbl.pdf."},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib98","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib99","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhepr.2024.101116_bib100","unstructured":"US food and drug administration - pradaxa [cited 02.04.2024] [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022512s007lbl.pdf."},{"issue":"1","key":"10.1016\/j.jhepr.2024.101116_bib101","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/ijlh.12767","article-title":"Effect of Rivaroxaban on thrombin generation in\u00a0vivo. A study in obese patients","volume":"40","author":"Bertaggia-Calderara","year":"2018","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib102","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s12072-021-10247-x","article-title":"A\u00a0network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis","volume":"15","author":"Ng","year":"2021","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101116_bib103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40256-019-00369-x","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review","volume":"20","author":"Fu","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"25","key":"10.1016\/j.jhepr.2024.101116_bib104","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"Lee","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101116_bib105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.dld.2018.12.001","article-title":"Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis","volume":"51","author":"Chokesuwattanaskul","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101116_bib106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5114\/ceh.2023.130605","article-title":"Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation","volume":"9","author":"Baylo","year":"2023","journal-title":"Clin Exp Hepatol"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101116_bib107","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/10600280211047433","article-title":"Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis","volume":"56","author":"Oldham","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101116_bib108","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/10600280211025050","article-title":"Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study","volume":"56","author":"Coons","year":"2022","journal-title":"Ann Pharmacother"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924001204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924001204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:38:15Z","timestamp":1722973095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924001204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":108,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2589555924001204"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101116","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants in cirrhosis: Rationale and current evidence","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101116"}}